The Stand

Organize now to oppose lame-duck TPP

Print Friendly, PDF & Email

(Oct. 27, 2016) — Advocates for trade policies that bolster people and not just profits have successfully stalled a vote on the Trans-Pacific Partnership for more than a year and a half, but TPP proponents have pledged an all-out last ditch fight in the post-election lame-duck session of Congress.

Momentum to reject and renegotiate the TPP is growing both nationally with both presidential candidates’ outspoken opposition to the secretly negotiated deal, and locally with last week’s announcement by Rep. Denny Heck (D-10th) that he will join Rep. Adam Smith (D-9th) in voting against it.

tpp-call-in-day-16nov16TAKE A STAND — All labor, environmental, consumer and human-rights advocates are urged to mark their calendars and help spread the word about a National Call-In Day planned for Wednesday, Nov. 16. Download, post and share this flier to let your co-workers, friends, family and others know about this important effort. Also, sign up to participate in a Thunderclap of the Nov. 16 Call-In Day on social media.

Callers around Washington state will thank Reps. Heck and Smith for their opposition, and urge TPP opposition from the state’s Democratic Reps. Suzan DelBene, Rick Larsen and Derek Kilmer — who all claim they are still undecided more than a year after the TPP’s release — and the state’s Republican Reps. Jaime Herrera Beutler, Cathy McMorris Rodgers, Dan Newhouse and Dave Reichert, who all plan to vote for the TPP.

Meanwhile, check out the following letter sent to President Barack Obama today by the leaders of the AARP, AFL-CIO, Consumers Union (the policy arm of Consumer Reports magazine), Doctors Without Borders and Oxfam America. It describes how the TPP-implementing legislation that the Obama administration intend to put before Congress in the lame-duck session could lock in high prescription drug prices for years to come, blocking congressional and other efforts to rein in the skyrocketing costs of life-saving drugs:

tpp-obama-letter-drugs

October 26, 2016

President Barack Obama
The White House
1600 Pennsylvania Avenue NW
Washington, DC 20500

Dear President Obama:

As organizations that represent millions of Americans, including consumers, retirees, and patients, and that provide medical care globally, we are concerned about recent reports that your Administration is working behind the scenes to craft Trans-Pacific Partnership (TPP) implementing legislation and possibly enter into side letters that would mean even more lengthy monopoly protections for biologics than the already onerous provisions in the TPP agreement. It is our understanding that this could bind the United States to a 12-year market exclusivity period for biologics and block the U.S. and other countries from reducing the amount of time expensive biologic drugs are protected from competition from less expensive biosimilar drugs.

Throughout the TPP negotiations, our organizations called for provisions that improve both innovation and access to affordable medicines. Though we each have our own critiques of the TPP, we share a view that no TPP commitment should be taken to worsen the plight of Americans already struggling to afford the high and growing prices of prescription drugs, as are millions of people around the world. We salute your Administration for using your budget proposals to suggest ways to improve the affordability of prescription drugs, including reducing the current 12-year market exclusivity period for biologic drugs. We also strongly support your work to continue implementing the new biosimilar approval pathway to increase price competition.

Biologics are fast becoming the future of pharmaceuticals. These drugs are used to treat many diseases – such as multiple sclerosis, rheumatoid arthritis, cancer and others – that often affect older populations. However, the cost of these drugs can put these treatments out of reach for those who need them most, even those with comprehensive health insurance. The daily costs associated with biologics are approximately 22 times higher than the daily costs associated with small-molecule drugs. With annual costs that can reach as high as $600,000 per individual, the high price of biologic drugs not only has adverse effects on consumers, but also on taxpayer-funded programs like Medicare and Medicaid.

Reportedly, under your Administration’s discussions with key legislators the United States’ current 12-year market exclusivity period would be included in TPP implementing legislation. This would go beyond the TPP provisions that already require at least eight years of exclusivity, or at least five years of exclusivity plus additional protections. Binding the U.S. and any other TPP party to an international obligation that requires a 12 year exclusivity period would not only undermine your proposal but future proposals to provide no more than seven years of market exclusivity to enable lower cost biosimilars to come to market sooner.

A change that binds the U.S. government to a 12-year market exclusivity period for brand-name biologics would prevent U.S. policymakers from taking action to reduce the costs associated with biologic drugs. In fact, Senators Sherrod Brown (D-OH) and John McCain (R-AZ) and several House Democrats have introduced the Price Relief, Innovation, and Competition for Essential Drugs Act (PRICED Act), which would reduce the biologic market exclusivity period from 12 to seven years, as you have proposed in your budget. Providing for 12-years of market exclusivity as part of U.S. implementation of the TPP would mean accepting unnecessarily long drug monopolies at the expense of people’s health and financial solvency. According to the Federal Trade Commission, no exclusivity time is needed to promote innovation given patent protections and other market pricing incentives.

We strongly urge you not to include language in the TPP implementing legislation committing the United States to 12-years of exclusivity or enter into side letters to extend the biologics exclusivity period for any TPP signatory country. We ask you to stand by your previous support for reducing U.S. market exclusivity to seven years for high cost biologic medicines.

Sincerely,

Nancy A. LeaMond
Executive Vice President and Chief Advocacy & Engagement Officer
AARP

Richard L. Trumka
President, AFL-CIO

Laura MacCleery
Vice President, Consumer Policy and Mobilization
Consumers Union/Consumer Reports

Jason Cone
Executive Director
Medecins Sans Frontieres/Doctors Without Borders (MSF) USA

Raymond C. Offenheiser
President, Oxfam America

CC: Ambassador Michael Froman, United States Trade Representative

 

Short URL: http://www.thestand.org/?p=52921

Posted by on Oct 27 2016. Filed under NATIONAL. You can follow any responses to this entry through the RSS 2.0. Both comments and pings are currently closed.

Comments are closed

WASHINGTON IS A UNION STATE!

Union membership is on the rise here in Washington state. CLICK HERE to find out why, and how YOU can get started forming a Union at your workplace!

WHAT’S HAPPENING

Archives

Log in | Designed by Gabfire themes